CNS PHARMACEUTICALS, INC.

(CNSP)
  Rapport
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op CNS PHARMACEUTICALS, INC.
2020CNS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
2020WPD Pharmaceuticals Inc. Partners with CNS Pharmaceuticals, Inc. on Drug Development fo..
2020CNS PHARMACEUTICALS : Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates ..
2020CNS Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Year Ende..
2020CNS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Resu..
2020CNS PHARMACEUTICALS : Announces Business Highlights and 2019 Fourth Quarter Financial Resu..
2020CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2020CNS PHARMACEUTICALS : to Report Fourth Quarter 2019 Financial Results on March 12, 2020
2020WPD Pharmaceuticals’ Brain Cancer Drug Received Positive FDA Pre-IND Guidance
2020CNS PHARMACEUTICALS : Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains ..
2020CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains..
2020CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2020CNS PHARMACEUTICALS : to Ring Nasdaq Stock Market Opening Bell on March 3
2020WPD Pharmaceuticals Inc. Plans to Initiate A Phase I Clinical Trial for Berubicin in Pe..
2020CNS PHARMACEUTICALS : Announces Collaboration with European Partner to Expand Clinical Tri..
2020CNS Pharmaceuticals, Inc. Announces Plan to Initiate Phase I Clinical Trial for Berubic..
2020CNS PHARMACEUTICALS : Announces Completion of GMP Manufacturing
2020CNS Pharmaceuticals, Inc. Announces Completion of GMP Manufacturing
2020CNS PHARMACEUTICALS : Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance
2020CNS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disc..
2020CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2020CNS PHARMACEUTICALS : Announces Contract with International GMP Manufacturer for Productio..
2020CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2020CNS PHARMACEUTICALS : Licenses Breakthrough Technology from MD Anderson, Doubling its Drug..
2019CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to Russell Microcap Growth Index
2019CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to Russell Microcap Value Index
2019CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to Russell Microcap Index
2019CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to S&P TMI Index
2019CNS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
2019Cns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended Septembe..
2019CNS PHARMACEUTICALS : Partnered with Anthem Biosciences Pvt. Ltd. in Preparation for Upcom..
2019CNS Pharmaceuticals Partners with Anthem Biosciences Pvt. Ltd. in Preparation for Upcom..
2019CNS PHARMACEUTICALS : ' Berubicin Awarded $5.8 Million Non-Dilutive Grant from EU/Polish N..
2019CNS PHARMACEUTICALS : Received Positive FDA Pre-IND Guidance for Berubicin
2019CNS Pharmaceuticals, Inc. Receives Positive FDA Pre-IND Guidance for Berubicin
2019CNS PHARMACEUTICALS : to Participate in the 8th Annual ROTH Deer Valley Corporate Access E..
2019CNS PHARMACEUTICALS : to Participate in 12th Annual LD Micro Main Event Conference
2019CNS PHARMACEUTICALS : Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
2019CNS Pharmaceuticals Enters $2.0 Million Dollar Sublicense Agreement with WPD Pharmaceut..
2019CNS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
2019CNS PHARMACEUTICALS : Announces Full Exercise of Over-Allotment Option
2019CNS PHARMACEUTICALS : Announces Attendance at the 24th Annual Meeting of the Society of Ne..
2019CNS PHARMACEUTICALS : Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmac..
2019CNS Pharmaceuticals, Inc. Acquired Worldwide Rights for Brain Cancer Drug from Houston ..
2019CNS Pharmaceuticals, Inc. Announces Executive Changes
2019CNS PHARMACEUTICALS : Announces Closing Of Initial Public Offering of Common Stock
2019CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to NASDAQ Composite Index
2019CNS Pharmaceuticals, Inc. has completed an IPO in the amount of $8.5 million.
2019CNS Pharmaceuticals, Inc. has filed an IPO in the amount of $10.625 million.
2019CNS Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
2018CNS Pharmaceuticals, Inc. announced that it has received $0.628558 million in funding
2018CNS Pharmaceuticals, Inc. announced that it expects to receive $1.07 million in funding
Vorig1  2  3   4
Volgende evenement op CNS PHARMACEUTICALS, INC.